Key facts
- It has raised $2.0M; the latest was Angel (individual) in Feb 2026.
- Notable investors include Creative Destruction Lab, MedTech Innovator, Matter (Consulting Services (B2B)), Investissement Quebec, 2048 Ventures — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for FemTherapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for FemTherapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FemTherapeutics
Developer of customizable gynecological prosthetic medical devices designed to personalize therapeutics for women. The company has developed a data and intelligence platform that leverages artificial intelligence and three-dimensional printing to produce the world's first category of patient-specific gynecological prosthetics and provides non-invasive pelvic health conditions and manages the symptoms of pelvic organ prolapse and stress urinary incontinence, enabling women to restore their quality of life through effective symptomatic relief.
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2019
- Employees
- 8
- Website
- femtherapeutics.com/
- Ownership
- Privately Held (backing)
FemTherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FemTherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FemTherapeutics in its N-PORT filings yet. We sweep new filings monthly.